...
SCNIMID

Scinai Immunotherapeutics Ltd.

HealthcareBiotechnology
$0.89
$0.00(+2.14%)
52W$0.61
$6.18
FinancialsValuationvs BNTX
Updated Feb 28, 12:00 AM
RSI52
RS Rating25/99
Beta0.60
Volatility102%
F-Score5/9
Mkt Cap$3.0B
WEAKENING

Price Action

5Y Daily
50 DMA150 DMA200 DMA

Technical Summary

WEAKENING

Scinai Immunotherapeutics Ltd. is in a technical downtrend, trading below key resistance levels with a broken trend structure. Relative strength is weak (RS Rating: 25), showing significant lag compared to the market leaders. Earnings growth of 67% provides fundamental context to the price action. Investors should exercise caution due to high volatility (102% annualized), which requires wider risk management.

Relative Strength
25
out of 99
Lagging
Trend Score
1/4
Minervini Criteria
WEAKENING
Risk (Beta)
0.60
vs S&P 500
DEFENSIVE
52W Position
5%
from 52W low
Near Low
Trend & Momentum Analysis

Trend Template (Minervini)

WEAKENING1/4 Criteria Met
CriterionValueStatus
Price > 50 SMA$0.84
50 SMA > 100 SMA$1.02
100 SMA > 150 SMA$1.19
150 SMA > 200 SMA$1.50

Price vs Moving Averages

PeriodValueSpreadSignal
20 SMA$0.84+6.19%ABOVE
50 SMA$0.84+5.94%ABOVE
100 SMA$1.02-13.01%BELOW
150 SMA$1.19-25.40%BELOW
200 SMA$1.50-40.93%BELOW

Price Performance

1D+2.1%
1W+21.7%
1M-13.7%
3M-13.7%
6M-39.1%
YTD+21.7%
1Y-74.9%
3Y-66.5%
52-Week Trading Range5% from low
$0.89
52W Low$0.61
52W High$6.18

Technical Indicators

RSI (14)NEUTRAL
52.3
305070
VCP ScoreCOOL
5/10
Base depth: 77.3%

Risk Profile

Beta
0.60
52W Vol
102%
ATR
$0.07
Max DD (1Y)
-82%

Volume Analysis

Today
—
50D Avg
41.7K
Vol Ratio
0.00x
Liquidity
ILLIQUID

Earnings Momentum

Q3'24-100%
$12.40
Q4'24+15%
$-8.80
Q1'25+73%
$-1.20
Q2'25+67%
$-1.20
Fundamentals & Growth

Growth Trends

Compounded Sales Growth

10 Years:—
5 Years:—
3 Years:—
TTM:+303.87%

Compounded Profit Growth

10 Years:—
5 Years:—
3 Years:—
TTM:-100.00%

Stock Price CAGR

10 Years:-45.78%
5 Years:-71.04%
3 Years:-66.46%
1 Year:-74.90%

Return on Equity

10Y Avg:-236.2%
5Y Avg:-329.1%
3Y Avg:177.4%
Last Year:58.7%

Key Metrics

Market Cap$3.0B
Gross Margin-88.1%
Net Margin7.3%
Piotroski F-Score5/9

More SCNI Analysis

Full Financial AnalysisDCF & Intrinsic ValueTotal Return Calculator

Compare With

SCNI vs BNTXBNTXMRNASMMTPCVX

Data Dictionary

RS Rating (Relative Strength)

Measures 12-month price performance vs all stocks. Rating of 25 meansSCNI outperformed 25% of all stocks. Scores >80 indicate market leaders.

Beta

Measures volatility vs S&P 500. Beta of 0.60 means 40% less volatile than market.

Piotroski F-Score

9-point financial strength score based on profitability, leverage, and efficiency. Score of 5/9. Scores 7-9 = strong, 4-6 average, 0-3 = weak.

VCP (Volatility Contraction Pattern)

Measures base formation quality. Higher scores indicate tighter consolidation near pivot points. Score of 5/10 with COOL status.

Frequently Asked Questions

Is SCNI in an uptrend right now?

SCNI has a trend score of 1/4 based on Minervini's Stage Analysis. Currently showing broken structure - 1 of 4 trend criteria are met.

Is SCNI overbought or oversold?

SCNI's RSI (14) is 52. The stock is in neutral territory, neither overbought nor oversold.

Is SCNI outperforming the market?

SCNI has a Relative Strength (RS) Rating of 25 out of 99. SCNI is currently lagging the broader market.

Where is SCNI in its 52-week range?

SCNI is trading at $0.89, which is 14% of its 52-week high ($6.18) and 5% above its 52-week low ($0.61).

How volatile is SCNI?

SCNI has a Beta of 0.60 and 52-week volatility of 102%. It's less volatile than the S&P 500 - generally more stable.